BOLT vs. FBIO, EBS, RGLS, NXTC, APLM, CLNN, RMTI, AADI, MRKR, and NBRV
Should you be buying Bolt Biotherapeutics stock or one of its competitors? The main competitors of Bolt Biotherapeutics include Fortress Biotech (FBIO), Emergent BioSolutions (EBS), Regulus Therapeutics (RGLS), NextCure (NXTC), Apollomics (APLM), Clene (CLNN), Rockwell Medical (RMTI), Aadi Bioscience (AADI), Marker Therapeutics (MRKR), and Nabriva Therapeutics (NBRV). These companies are all part of the "pharmaceutical preparations" industry.
Fortress Biotech (NASDAQ:FBIO) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.
Fortress Biotech has a net margin of -74.12% compared to Fortress Biotech's net margin of -878.58%. Fortress Biotech's return on equity of -51.18% beat Bolt Biotherapeutics' return on equity.
Fortress Biotech has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.
Fortress Biotech has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.
96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 33.4% of Fortress Biotech shares are held by company insiders. Comparatively, 28.4% of Bolt Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Fortress Biotech received 243 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. However, 68.38% of users gave Bolt Biotherapeutics an outperform vote while only 64.86% of users gave Fortress Biotech an outperform vote.
Fortress Biotech currently has a consensus target price of $30.00, indicating a potential upside of 1,644.19%. Bolt Biotherapeutics has a consensus target price of $7.00, indicating a potential upside of 530.63%. Given Bolt Biotherapeutics' higher possible upside, equities analysts plainly believe Fortress Biotech is more favorable than Bolt Biotherapeutics.
In the previous week, Bolt Biotherapeutics had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 2 mentions for Bolt Biotherapeutics and 1 mentions for Fortress Biotech. Bolt Biotherapeutics' average media sentiment score of 0.00 beat Fortress Biotech's score of -0.16 indicating that Fortress Biotech is being referred to more favorably in the media.
Summary
Fortress Biotech beats Bolt Biotherapeutics on 12 of the 17 factors compared between the two stocks.
Get Bolt Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BOLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bolt Biotherapeutics Competitors List
Related Companies and Tools
